1. Home
  2. EOLS vs NKX Comparison

EOLS vs NKX Comparison

Compare EOLS & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EOLS
  • NKX
  • Stock Information
  • Founded
  • EOLS 2012
  • NKX 2002
  • Country
  • EOLS United States
  • NKX United States
  • Employees
  • EOLS N/A
  • NKX N/A
  • Industry
  • EOLS Biotechnology: Pharmaceutical Preparations
  • NKX Finance/Investors Services
  • Sector
  • EOLS Health Care
  • NKX Finance
  • Exchange
  • EOLS Nasdaq
  • NKX Nasdaq
  • Market Cap
  • EOLS 493.5M
  • NKX 562.3M
  • IPO Year
  • EOLS 2018
  • NKX N/A
  • Fundamental
  • Price
  • EOLS $7.19
  • NKX $12.49
  • Analyst Decision
  • EOLS Strong Buy
  • NKX
  • Analyst Count
  • EOLS 5
  • NKX 0
  • Target Price
  • EOLS $21.25
  • NKX N/A
  • AVG Volume (30 Days)
  • EOLS 899.1K
  • NKX 109.3K
  • Earning Date
  • EOLS 11-05-2025
  • NKX 01-01-0001
  • Dividend Yield
  • EOLS N/A
  • NKX 4.37%
  • EPS Growth
  • EOLS N/A
  • NKX N/A
  • EPS
  • EOLS N/A
  • NKX N/A
  • Revenue
  • EOLS $277,941,000.00
  • NKX N/A
  • Revenue This Year
  • EOLS $14.01
  • NKX N/A
  • Revenue Next Year
  • EOLS $29.46
  • NKX N/A
  • P/E Ratio
  • EOLS N/A
  • NKX N/A
  • Revenue Growth
  • EOLS 17.15
  • NKX N/A
  • 52 Week Low
  • EOLS $5.71
  • NKX $9.78
  • 52 Week High
  • EOLS $17.82
  • NKX $12.00
  • Technical
  • Relative Strength Index (RSI)
  • EOLS 42.33
  • NKX 80.61
  • Support Level
  • EOLS $7.19
  • NKX $11.75
  • Resistance Level
  • EOLS $7.75
  • NKX $11.87
  • Average True Range (ATR)
  • EOLS 0.31
  • NKX 0.10
  • MACD
  • EOLS 0.05
  • NKX 0.07
  • Stochastic Oscillator
  • EOLS 0.65
  • NKX 88.92

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: